company background image
INVA

Innoviva NasdaqGS:INVA Stock Report

Last Price

US$16.09

Market Cap

US$1.1b

7D

5.3%

1Y

26.0%

Updated

16 May, 2022

Data

Company Financials +
INVA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health4/6
Dividends0/6

INVA Stock Overview

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally.

Innoviva Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Innoviva
Historical stock prices
Current Share PriceUS$16.09
52 Week HighUS$20.71
52 Week LowUS$11.90
Beta0.50
1 Month Change-15.45%
3 Month Change-18.28%
1 Year Change26.00%
3 Year Change13.23%
5 Year Change33.20%
Change since IPO-11.15%

Recent News & Updates

Mar 04
We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Feb 21

Taking Innoviva Winnings Off The Table, Again

I think Innoviva's recent financial results have been quite good in many ways. Both revenue and net income are materially higher than both 2020 and 2019. I think Innoviva management likely overpaid for the stock buyback, but this isn't the worst thing in the world, in my view. The worst thing is the valuation here. Last month's short puts are now even deeper out of the money, and the bid has collapsed as a result. So I'm selling INVA stock and maintaining my short put position.

Shareholder Returns

INVAUS PharmaceuticalsUS Market
7D5.3%3.0%0.7%
1Y26.0%10.8%-10.8%

Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: INVA exceeded the US Market which returned -10.4% over the past year.

Price Volatility

Is INVA's price volatile compared to industry and market?
INVA volatility
INVA Average Weekly Movement5.2%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: INVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: INVA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19965Pavel Raifeldhttps://www.inva.com

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.

Innoviva Fundamentals Summary

How do Innoviva's earnings and revenue compare to its market cap?
INVA fundamental statistics
Market CapUS$1.11b
Earnings (TTM)US$187.50m
Revenue (TTM)US$396.41m

6.0x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INVA income statement (TTM)
RevenueUS$396.41m
Cost of RevenueUS$6.37m
Gross ProfitUS$390.04m
Other ExpensesUS$202.54m
EarningsUS$187.50m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.69
Gross Margin98.39%
Net Profit Margin47.30%
Debt/Equity Ratio97.6%

How did INVA perform over the long term?

See historical performance and comparison

Valuation

Is Innoviva undervalued compared to its fair value and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: INVA ($16.09) is trading below our estimate of fair value ($198.34)

Significantly Below Fair Value: INVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: INVA is good value based on its PE Ratio (6x) compared to the US Pharmaceuticals industry average (20.4x).

PE vs Market: INVA is good value based on its PE Ratio (6x) compared to the US market (15.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INVA is overvalued based on its PB Ratio (2.9x) compared to the US Pharmaceuticals industry average (1.7x).


Future Growth

How is Innoviva forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-4.3%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if INVA's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if INVA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INVA's revenue is expected to decline over the next 3 years (-4.3% per year).

High Growth Revenue: INVA's revenue is forecast to decline over the next 3 years (-4.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: INVA's Return on Equity is forecast to be low in 3 years time (16.1%).


Past Performance

How has Innoviva performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


11.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: INVA has high quality earnings.

Growing Profit Margin: INVA's current net profit margins (47.3%) are lower than last year (73.7%).


Past Earnings Growth Analysis

Earnings Trend: INVA's earnings have grown by 11.9% per year over the past 5 years.

Accelerating Growth: INVA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: INVA had negative earnings growth (-25.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).


Return on Equity

High ROE: INVA's Return on Equity (53.8%) is considered outstanding.


Financial Health

How is Innoviva's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: INVA's short term assets ($317.8M) exceed its short term liabilities ($109.2M).

Long Term Liabilities: INVA's short term assets ($317.8M) do not cover its long term liabilities ($446.0M).


Debt to Equity History and Analysis

Debt Level: INVA's net debt to equity ratio (58.3%) is considered high.

Reducing Debt: INVA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: INVA's debt is well covered by operating cash flow (70.1%).

Interest Coverage: INVA's interest payments on its debt are well covered by EBIT (24.7x coverage).


Balance Sheet


Dividend

What is Innoviva current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate INVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INVA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: INVA is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as INVA has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average board tenure


CEO

Pavel Raifeld (37 yo)

2yrs

Tenure

US$1,271,138

Compensation

Mr. Pavel Raifeld, CFA, serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive with a strong background in strategy, business development and corporate fi...


CEO Compensation Analysis

Compensation vs Market: Pavel's total compensation ($USD1.27M) is below average for companies of similar size in the US market ($USD3.88M).

Compensation vs Earnings: Pavel's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: INVA's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Innoviva, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Innoviva, Inc.
  • Ticker: INVA
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.105b
  • Shares outstanding: 69.70m
  • Website: https://www.inva.com

Number of Employees


Location

  • Innoviva, Inc.
  • 1350 Old Bayshore Highway
  • Suite 400
  • Burlingame
  • California
  • 94010
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.